IMR Press / EJGO / Volume 24 / Issue 6 / pii/2003212

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Distinguished Expert Series

Current state-of-the-art of concomitant chemoradiation in cervical carcinomas

Show Less
1 Chairman of the Center of Oncology, University of Split School of Medicine, Clinical Hospital of Split, Croatia
2 Baxter Oncology, Frankfurt, Germany
Eur. J. Gynaecol. Oncol. 2003, 24(6), 475–479;
Published: 10 December 2003

Despite screening programs, cervical carcinoma remains a major health problem throughout the world. Until recently pelvic rad1- ation has been the standard therapy for advanced disease with overall five-year survival rates of 50%. Recently, five randomized trials demonstrated a significant survival advantage for the concomitant administration of radiotherapy and cisplatin-based chemotherapy. Although the trials vary somewhat in terms of stage of disease, dose of radiation, and schedule of radiation and cisplatin, they all demonstrated a significant survival benefit for the combined approach. Congruent to these findings are results from a meta-analysis based on the data from 19 trials with 4,580 randomized patients. The absolute increase in progression-free and overall survival was 16% and 12%, respectively. Contrary to these findings is the result of the National Cancer Institute of Canada (NCC]) trial. Despite that result cisplatin-based concomitant chemoradiotherapy has become the standard treatment of locally advanced cervical cancer.

Cervical cancer
Concomitant chemoradiotherapy
Back to top